Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is reasonable to think that EPA's anti-inflammatory effects would be helpful in infectious diseases, including Covid.
Nuke...A meaningfull stock offering would bring Amarin shares back down to their lowest prices of the year...I doubt that Denner would resort to a further dilution.
We were all paralyzed by the Judge Du decision...However, after the appeal was rejected, JT could have made the following moves...
-fire all reps
-start work on a FDC with V
-discontinue all TV adds
-introduce MND-2119 in the U.S. market...along with plans for a second FDC with MND-2119
-introduce an AG, slightly lower in price than Vascepa, into the U.S. market
-introduce an OTC EPA product
-fund studies to demonstrate that the gelatin capsule used by gV is inferior that of V in stopping oxidization of EPA
-fire in house legal counsel
-sue Covington for legal malpractice
-start an additional appeal of the invalidation of the Marine patent based on fraud on the Du court
-link share price to financial rewards for management
-select partners for Canada, Europe, and ROW
- hire an M and A consultant to explore sale of Amarin to a BP.
Many of these moves can still be undertaken by Sarissa.
note to KM...The votes are already in...What will be, will be...Why be paranoid, petty, and petulant?
All these points are true....but KM was new...and under the thumb of PWO.
Marjac...QUOTE...The legal malpractice suit is a win-win for both Amarin and its shareholders, as any money recovered after attorneys fees and expenses, is revenue for the Company.
"Amarin could use this revenue to make an effort to recover the U.S. market....something that is definitely not on the agenda of management at present.
Words of wisdom..." I think Amarin hasn't formed any further partnerships because they too know they want to maximize a buy-out."
Yes, but they just want to the ones to take the credit...Not Denner.
Amarin's failing efforts in Europe would make almost any buyout now look good...and so they waste all that shareholders money just to maintain their position in the drivers seat.
At one time I speculated that Amarin would go to $50/sh...Now I would take $5/sh.
PWO says to give him a year...But Amarin refuses to give any guidance..They're not worried about their shareholders losing their cash...but they don't want their own reputations smirched by not living up to their guidance.
I hope the BP that buys Amarin pays in stock...But if the BP pays in cash , I will use the cash to buy some stock in the fortunate BP.
Rose...QUOTE... "Heck if we simply look at statins, even amongst those that feel that they offer great benefit, no one, I believe, would say that they offer IMMEDIATE protection from CVD events"
Statins are already accepted as SOC(standard of care) through out the world...That is why a fixed dose combo with EPA and a statin would be more credible to Docs and patients as a way to reduce CVD....
At this time, most patients and many Docs have still never heard of Vascepa...but they have heard of statins....When they see a combo Rx for 'Vastatin', they won't have to ask..."what is this drug treating?"
After losing patent protection for V, this is a strategy, Amarin could have immediately turned to, knowing that competition for V from generics was coming soon.
This is not about individual board members not being the right board members...Its about the COB not being the right COB.
We need a COB with experience in the U.S....in R and D, accounting, regulatory issues, finance, M and A, and marketing.
Tats...Do you not think that taking a single combo drug per day, with either 20mgs or 40 mgs.of Lipitor, sprayed onto a capsule containing 2 grams of MND-2119, (VASTATIN) would be a widely accepted alternative to taking 4 capsules of Vascepa a day PLUS a statin, and would have an appeal for many patients?...It would certainly be appealing to me.
Adding a statin to Vascepa would also give it more legitimacy to Doctors.
Tats..Thank you for your take...Do you think that a patent on a combo drug for a 2 gram capsule, containing MND-2119 plus a statin sprayed on the capsule, could be successfully challenged by the generics?
Laura...I am not the best person to ask because, if I were a good investor, I wouldn't still be here... but here's my take...
-If Denner wins, Amarin has a decent chance to head up in the near term and in the next few years.
-If PWO wins(this is really a battle between PWO and Denner) the stock is almost definitely heading down.
Ramfan...MND-2119 is never mentioned by Amarin even though they paid $2 million for the rights to sell Mochida products anywhere but in Japan....MND-2119 has been approved in Japan and is currently being marketed there...It is also an EPA drug, but one, which better absorbed by the body than Vascepa.
negative features
1. It would have to go through an approval process by the U.S. FDA
2. It would replace Vascepa, which Amarin has already inventoried a ton of
3. It would need a whole new marketing campaign, which Amarin can't afford
4. It would probably cost Amarin in royalties(?how much...Amarin won't divulge)
positive features
1. It would be a patented drug in the U.S. without any generic competition
2. It could be given in 2 gram capsules to produce the same blood levels as 4
gram capsules of Vascepa
3. It would be a better combination drug for a FDC drug than Vascepa
"As this was a different proxy form that [the registrar] had seen before, we had to check with Amarin if we were to accept it."
Apparently the registrar was not accepting the blue cards UNTIL SARISSA told them that they were legally required to accept them.
Many who received only white cards may have figured they had already voted and ignored the blue cards when they came afterwards.
"Amarin’s registrar, the firm retained by Amarin to receive and process proxy cards, had not been instructed to accept blue proxy cards even though legally required to do so."
This is an unforgivable "mistake" by Amarin...i.e. to line up the cards in their favor(or is it just another example of management's incompetence)?...Where is Marjac?
Pdude...QUOTE..."Denner will have complete control. Absolute control. WS knows this and a vote to add all 7 members will tank the stock as WS sees this as destabilizing the company. Senior Amarin staff in EU who are organizing the launch will see the writing on the wall and will start to abandon ship at the first opportunity."
I disagree..Denner will have the option of rehiring KM...or hiring one of his top associates...in addition to hiring an executive for the U.S.
Even if Amarin is sold , it is much better for executives' future careers to have been associated with a winning situation rather than a loser.
CBB..."NOW BCBS will not even cover the drug"....If important BCBS bureaucrats decided to cover Vascepa, followed by millions of patients quickly asking for prescriptions to cover it, BCBS might lose money in that quarter... causing the bureaucrats to be fired and have heart attacks themselves."
I agree...A CEO for the U.S. in addition to a CEO for Europe and ROW, are now needed for Vascepa and other EPA drugs....I'm surprised this hasn't happened already. One CEO can not adequately do justice to the entire global market.
Question...Which individual at Amarin is presently responsible for the U.S. market?...I believe a BP would attend to this matter appropriately.
NS You are correct...There are many things up in the air in the near and long term...
-what will revenues be in the U.S.?
-what will revenues be in Europe and ROW?
-has the U.S. market really been lost forever?
-How will the FDC combo succeed in Europe?
-will there be one or more BP interested in buying Amarin?
- how will the stock market fare in the next months and years?
- how low a buyout price would be acceptable?
At this point, neither the Amarin board nor Denner have answers to these questions...
But I trust that Denner will eventually sell the company at a profit to where he bot.
MEA Culpa...After the Anchor debacle and especially after the Anchor results results were known...I, along with J.L., was one of those, who were against a sale of Amarin.
BOY...have I changed my mind!...The future of EPA drugs still looks promissing...but NOT with Amarin.
We have been focusing on which will give us the greater rewards....i.e. going with PWO or going with Denner....We should also be discussing which will give us the greater risks....in the short term and also in the long term.
NS...I would prefer Denner to replace PWO with himself....to facilitate the sale of Amarin.
Pdude...I agree about Germany...The only criticism of KM I have with regards to the the Germany episode is that we should had a warning that there might be trouble in dealing with them...as we only now have come to realize.
With regards to KM...If I were in the same position as he is presently in, I probably would be giving talks, similar to what he now saying...KM came to Amarin AFTER the Du debacle and is in no way responsible for that tragic mistake....KM would be an asset to whichever company buys Amarin.
NS...Amarin owns Vascepa, a gem that needs polishing...
QUOTE..."What will future revenue and profits be in the EU? I can't guess"...
Let me guess....Europe is beset by inflation and diminishing resources...The future for Vascepa revenues and profits in Europe look dim
U.S. revenues are still what are holding Amarin up...Vascepa needs to figure out a way to regain more of the the U.S. market....Europe, by itself, can not be the salvation for Amarin....KM has done the best he could in Europe...Now we need to return to a U.S. focused strategy. That is why Amarin needs to be sold.
The thing I liked least about the teleconference this AM was the apparent message that reclaiming the U.S. market was out of the equation for Amarin.
Whichever BP buys Amarin should have a CEO for the U.S. and one for Europe and ROW
In the U.S.,The following should be under consideration.....
1.An AG for Vascepa
2. replacing Vascepa with MND2119
3. A FDC with a statin and Vascepa
4. A FDC with a statin and MND-2119
5. Indications for other diseases with an inflammatory component....such as Alzheimers, rheumatoid arthritis, cancer, dry eyes etc.
6. The acquiring company needs to return to having reps and TV adds to market its products.
Amarin absolutely can not do these things alone...It has to sell to a BP.
orbapu...If Sarissa feels that KM is valuable to Amarin, I'm sure they can work together for the good of both of each of them...criticisms aside.
Robin...Can you imagine a case where, in a proxy fight, a proxy company is hired by one party or the other...and then votes against the party that hired them?...NO WAY!!!
Pay little attention to Glass-Lewis or to Sarissa or even to the I-HUB board...Vote on your knowledge of Amarin and its good points and bad points... and especially on your common sense.
622 fast...once a decision has been made that a company needs to be be sold, the next issue to be decided is.... What is more important to the current management...the benefits received from the jobs that management currently has...or the benefits received by current management from a sale of the company?
In the case of Amarin, I fear that for current management, it is one thing..and for Denner, it is another thing....I side with Denner.
golf...Erikson didn't care a fig about Amarin, selling all of Serofina's Amarin stock...Then he was followed by PWO as his handpicked successor....I agree that Erikson and then PWO have had the final say...Amarin now needs someone,who has contributed $100 million of his OWN cash...to call the shots as to which board members are the most crucial in maintaining and elevating the share price...and then selling the company.
Robin...Paying Glass-Lewis for their services is normal as long as Amarin and Glass-Lewis make note of that fact(as a potential conflict of interest)...I don't believe either of them did that.
It was a valuable discussion in that it highlighted that KM has critical expertise for Europe and Berger has the same for mergers and acquisitions....They would both be valuable to a BP.
duke...I too was perplexed as to why they have suddenly have lost any interest in the U.S. market...I guess this is because they just don't have the cash...and they were unwilling to mention it.
I have no confidence that in a year from now, they will have any more cash available for new promotions...even for Alzheimers.
This was a very good shareholder discussion... It pointed out clearly the many strengths of Vascepa(EPA)...
There was a total agreement by the board that the U.S. market is lost...but that doesn't have to be the case...if a BP, with greater assets, could use patented MND-2119 in a FDC to reclaim the U.S, market and still be household name in Europe and ROW.....Amarin , unfortunately, was denied those assets by the decision of judge Du....and now has to sell to a BP.
Amarin and/or Glass-Lewis need to issue a disclaimer if hired by Amarin....Amarin describes Glass-Lewis as...QUOTE..."Leading INDEPENDENT Proxy Advisory Firm Glass Lewis"
STS...A subscription license makes sense...The National health service buys a subscription license for x number of years and pays a flat rate... as the volume increases, the license rate also increases...but at a slower rate than the volume increase.
As the national Health service comes to realize that they are saving money by using EPA for more of their citizens, due to a reduction in CVD, they will agree to pay more for the subscription....Its a win-win....for the National health service and the drug company...not to mention, for the patients.
TTE...This is the kind of a payroll package that a BP might have...This is another reason why Amarin needs to be sold to a BP.
Canes...I am willing to wait two years, but only if a new EPA product, such a FDC(preferably with MND-2119 and a statin), can be introduced into the U.S. with the advantage of patent exclusivity....That can be done only if Amarin is sold to a BP.
The dream of Amarin GIA and becoming a BP, by itself, ended with the judge Du decision.
The dream lives on with current management, but it is only a mirage.
This blue and white card conundrum(along with the wording of the cards) is quite confusing and may lead to misunderstandings by those, who are voting....Why not have one card with all the participants...then you can vote yea or no on each candidate...with the 14 candidates who ,collect most yea votes, being declared as the winners?